College Hill Life Sciences Further Grows its Portfolio of New Clients
19 February 2013, London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, has continued to add to its portfolio of clients with six new client wins to date in 2013 from across both Europe and Australia. New clients include both private and listed companies, with mandates ranging from fully retained services to branding and IR/PR projects.
In Europe, the team has been commissioned by France-based Nanobiotix, Austria-based Hookipa Biotech, and Germany-based AiCuris.
Paris-based Nanobiotix (Euronext: NANO) is a nanomedicine company dedicated to the development of new treatments for cancer. Listed on Euronext in 2012, it has retained College Hill to support its financial and corporate communications internationally.
Hookipa Biotech, a venture-backed company developing a new class of innovative prophylactic and therapeutic vaccines, has sought input from College Hill to support its corporate communications needs in particular on its corporate identity and website together with media relations outreach.
AiCuris is a private company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases based around Bayer's portfolio of antiviral and antibacterial R&D programs, compounds and intellectual property. College Hill has supported media outreach on a project basis.
From Australia, new clients include ASX-listed Antisense Therapeutics as well as Medical Research Commercialisation Fund (MRCF) portfolio companies, Polyactiva and Helmedix.
Antisense Therapeutics (ASX: ANP) is a publicly traded pharmaceutical drug discovery and development company whose mission is to create, develop and commercialise novel antisense therapeutics. College Hill is supporting its financial communications through an investor/analyst/media roadshow in London.
Melbourne-headquartered Polyactiva has engaged College Hill Life Sciences to support media relations outreach around its drug delivery technology. It uses a unique drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films or fibres.
Helmedix, a new start up based on technology from the ithree institute at the University of Technology Sydney (UTS), has chosen College Hill to design its logo and to manage its first news release announcing its seed financing. It is developing novel therapies for autoimmune diseases based on an immune-modulating peptide derived from a helminth parasite.
“Many commentators have suggested that 2013 will be a good year for biotech companies and we are delighted to have been chosen by these new clients to support them in using brand building and business communications to support value creation”, said Sue Charles, Managing Partner at College Hill Life Sciences.
For further information:
+44 (0)20 7457 2020
back to news